Stoke Therapeutics, Inc.

NasdaqGS:STOK Stock Report

Mkt Cap: US$372.2m

Stoke Therapeutics Dividend

Dividend criteria checks 0/6

Stoke Therapeutics, Inc. does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.5%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareUS$0
Earnings per share-US$2.53
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Dec 13
We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Aug 14
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M

Aug 08

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Apr 29
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

Jan 13
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Sep 30
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Jun 16
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics EPS misses by $0.02

May 10

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap

Dec 14

Stoke Therapeutics prices $97.5M public offering

Nov 20

Stoke Therapeutics -2.7% AH, proposes public offering

Nov 18

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Nov 18
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics EPS in-line

Nov 12

Stability and Growth of Payments

How stable has Stoke Therapeutics's dividend per share been in the past?
MonthDividend Per Share (annual)Avg. Yield (%)
12/31/2024-1
12/31/2023-2

Stable Dividend: Insufficient data to determine if STOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STOK's dividend payments have been increasing.


Dividend Yield vs Market

Stoke Therapeutics Dividend Yield vs Market
How does STOK dividend yield compare to the market?
SegmentDividend Yield
Company (STOK)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.5%
Analyst forecast in 3 Years (STOK)0%

Notable Dividend: Unable to evaluate STOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as STOK has not reported any payouts.


Discover strong dividend paying companies